This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
by Zacks Equity Research
DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
Patterson Companies (PDCO) Aims to Streamline Patient Experience
by Zacks Equity Research
Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
by Zacks Equity Research
Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
by Zacks Equity Research
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are a concern.
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
by Zacks Equity Research
Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.
3 Reasons Why You Should Hold McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson's (MCK) robust Biologics business raises optimism about the stock.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark
by Zacks Equity Research
Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.
Philips (PHG) Gains Despite Recall of SENSE XL Torso Coils
by Zacks Equity Research
Philips (PHG) issues an urgent recall of SENSE XL Torso coils (1.5T and 3.0T) due to heating risks during MRI scans.
Here's Why You Should Add DaVita (DVA) to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
Masimo (MASI) Gets Non-Binding Offer for Consumer Business
by Zacks Equity Research
Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.
GE HealthCare's (GEHC) New Solution to Aid Prostate Treatment
by Zacks Equity Research
GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
by Zacks Equity Research
Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
by Zacks Equity Research
IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance
by Zacks Equity Research
Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.
Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit
by Zacks Equity Research
Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
by Zacks Equity Research
The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DaVita HealthCare (DVA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $137.92, signifying a +0.39% move from its prior day's close.
Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod
by Zacks Equity Research
Olink's (OLK) buyout by Thermo Fisher gets CMA's approval, signaling regulatory confidence in the merger's compliance with competition laws.